Zachary Roberts
CIK: 0001851044
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Allogene Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 1, 2026ALLO
Allogene Therapeutics, Inc.
Award(A)DirectRestricted Stock Unit
134.5K shares- - Jul 1, 2026ALLO
Allogene Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
476.2K shares- - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
Award(A)DirectRestricted Stock Unit
203.3K shares- - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
Sale(S)Direct35.7K shares at avg. $1.77$63K - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
718.8K shares- - Jan 21, 2026ALLO
Allogene Therapeutics, Inc.
Sale(S)Direct26.3K shares at avg. $1.56$41K - Feb 3, 2025ALLO
Allogene Therapeutics, Inc.
Sale(S)Direct18.8K shares at avg. $1.70$32K - Jan 24, 2025ALLO
Allogene Therapeutics, Inc.
Award(A)Direct173.9K shares- - Jan 21, 2025ALLO
Allogene Therapeutics, Inc.
Sale(S)Direct27.2K shares at avg. $1.78$48K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 1, 2026 | ALLO Allogene Therapeutics, Inc. | Award(A) Restricted Stock Unit | 134,530 | - | - | Direct |
| Jul 1, 2026 | ALLO Allogene Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 476,190 | - | - | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Award(A) Restricted Stock Unit | 203,307 | - | - | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Sale(S) | 35,700 | $1.77 | $63,189 | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 718,763 | - | - | Direct |
| Jan 21, 2026 | ALLO Allogene Therapeutics, Inc. | Sale(S) | 26,269 | $1.56 | $40,980 | Direct |
| Feb 3, 2025 | ALLO Allogene Therapeutics, Inc. | Sale(S) | 18,832 | $1.70 | $32,014 | Direct |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | Award(A) | 173,913 | - | $0 | Direct |
| Jan 21, 2025 | ALLO Allogene Therapeutics, Inc. | Sale(S) | 27,199 | $1.78 | $48,414 | Direct |
1-9 of 9 transactions
About Roberts Zachary
Roberts Zachary (SEC CIK 0001851044) files insider reports with the SEC as President and CEO of Allogene Therapeutics, Inc. (ALLO).
Signal8 holds 6 ownership filings by Roberts Zachary, all Form 4s, filed between Jan 23, 2025 and Jul 6, 2026. Those filings report 9 transactions, from Jan 21, 2025 to Jul 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Roberts Zachary's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Roberts Zachary
- Jul 1, 2026: Grants or awards of ALLO derivative securities (2 lines, Form 4, code A).
- Feb 2, 2026: Grant or award of ALLO derivative securities (Form 4, code A).
- Feb 2, 2026: Open-market sale of ALLO shares (Form 4, code S).
- Feb 2, 2026: Grant or award of ALLO derivative securities (Form 4, code A).
- Jan 21, 2026: Open-market sale of ALLO shares (Form 4, code S).
Other insiders filing for Allogene Therapeutics, Inc. (ALLO)
- Parker Geoffrey M., CHIEF FINANCIAL OFFICER
- Douglas Earl Martin, SVP, General Counsel
- Kazam Joshua A, Director
- MESSEMER DEBORAH M., Director
- Mayo Stephen, Director
- SATO VICKI L, Director